TRANSGENE BIOTEK LTD.

Transgene Biotek Ltd has announced a Board of Directors meeting scheduled for August 7, 2026. The primary agenda items include the consideration and approval of the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026, along with the Limited Review Report. The board will also discuss seeking an extension for the Annual General Meeting for FY 2025-26 and the appointment of the internal auditor for FY 2026-27. The company also informed that the trading window has been closed from July 1, 2026, until 48 hours after the financial results become public.

Transgene Biotek Ltd has stated that the Statement of Deviation or Variation for proceeds of public issue, rights issue, preferential issue, or QIP is not applicable for the quarter ended June 30, 2026. This is because the company had no such issues during the reporting period. The company also noted that it was unable to file the statement in XBRL mode as the form does not permit NIL entries.

Transgene Biotek Ltd has announced the closure of its trading window for all insiders and designated persons, including their immediate relatives. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will remain shut from July 1, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter ending June 30, 2026. The specific date for the board meeting to consider these results will be communicated later.

Transgene Biotek Ltd has announced a meeting of its Board of Directors on May 29, 2026, to consider and approve the audited financial results (standalone and consolidated) for the fourth quarter and financial year ended March 31, 2026. The meeting will also address any other business matters with the chair's permission.

Transgene Biotek Ltd. announced that Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, concerning the Statement of Deviation or Variation, is not applicable for the quarter ended March 31, 2026. This is due to the absence of any public issue, rights issue, or preferential issue during the reporting quarter. The company referenced SEBI circular CIR/CFD/CMD1/162/2019, which specifies the requirement for such a statement only when proceeds from these issues exist. The company also noted a technical issue preventing XBRL filing for NIL entries.

Transgene Biotek Ltd has announced the closure of its trading window for dealing in the securities of the company. The closure is in accordance with the Code of Conduct for Prevention of Insider Trading under SEBI regulations. The window will remain closed from April 1, 2026, till 48 hours after the declaration of financial results for the quarter and year ended March 31, 2026. This applies to all designated persons, their immediate relatives, and all connected persons covered under the company’s Code of Conduct. The date of the Board of Directors' meeting to approve the Audited financials results will be informed in due course.

Transgene Biotek Ltd has approved its unaudited Consolidated & Stand- alone Financial Results for the quarter ended 31.12.2025. The company's Board has considered and approved the results in accordance with the Indian Accounting Standards (IND-AS) as per Companies (Indian Accounting Standards) Rules, 2015. A Limited Review Report on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended 31.12.2025 has also been approved.

Transgene Biotek Ltd has approved the unaudited Consolidated & Stand-alone Financial Results for the quarter ended 31.12.2025. The company's financial results have been prepared in accordance with the Indian Accounting Standards (IND-AS) as per Companies (Indian Accounting Standards) Rules, 2015. The Limited Review Report on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended 31.12.2025 has also been approved.

Transgene Biotek Ltd has received a prohibitory order from the Securities and Exchange Board of India (SEBI) for failing to pay a penalty of Rs. 38 lacs. The penalty is in relation to a SEBI adjudication order dated 27th June 2022. Despite the company's appeal to the Securities Appellate Tribunal at Mumbai on 7th October 2022, the recovery proceedings have been initiated. The order prohibits the company from disposing, transferring, alienating, or charging all immovable and movable properties, and freezes all bank accounts. This has resulted in the halting of payments, including salaries, bringing all activities to a standstill.

Transgene Biotek Ltd has informed the BSE about a scheduled Board of Directors meeting on 13th February 2026. The meeting will consider and approve the Un-Audited Financial Results (Standalone & Consolidated) for the quarter ended 31st December 2025, along with the Limited Review Report (Standalone & Consolidated) for the same quarter. The meeting will also transact other necessary business. The trading window for dealing in the securities of the company was closed from 1st January 2026 till 48 hours after the financial results become generally available information, in accordance with the SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018.